Emergent BioSolutions Inc. (EBS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 700M 1.4B 2.1B FY09: 234.8M FY10: 286.2M FY11: 273.4M FY12: 281.9M FY13: 312.7M FY14: 450.1M FY15: 522.8M FY16: 488.8M FY17: 560.9M FY18: 782.4M FY19: 1.1B FY20: 1.6B FY21: 1.8B FY22: 1.1B FY23: 1B FY24: 1B FY25: 742.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 350M 700M 1.1B FY20: 925.2M FY21: 891.3M FY22: 383M FY23: 317.6M FY20 FY21 FY22 FY23

Operating Income Annual

-750M -500M -250M 0 250M 500M 750M FY09: 40.1M FY10: 73.6M FY11: 32.1M FY12: 30M FY13: 42.8M FY14: 89.2M FY15: 141.5M FY16: 105.5M FY17: 124.3M FY18: 89.8M FY19: 114.1M FY20: 438.5M FY21: 341.4M FY22: -170M FY23: -726.4M FY24: -108.7M FY25: 100.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-900M -600M -300M 0 300M 600M 900M FY09: 31.1M FY10: 51.7M FY11: 23M FY12: 23.5M FY13: 31.1M FY14: 36.7M FY15: 62.9M FY16: 51.8M FY17: 82.6M FY18: 62.7M FY19: 54.5M FY20: 305.8M FY21: 219.5M FY22: -211.6M FY23: -760.5M FY24: -190.6M FY25: 52.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 300M 600M 900M FY16: 126.3M FY17: 187.7M FY18: 322.3M FY19: 433.5M FY20: 537M FY21: 748.1M FY22: 693.1M FY23: 705.4M FY24: 681.3M FY25: 326.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-400M -200M 0 200M 400M 600M FY09: 29.9M FY10: 98M FY11: 12.2M FY12: 39.6M FY13: 97M FY14: 112.3M FY15: 42.5M FY16: 54.6M FY17: 208.1M FY18: 41.8M FY19: 188M FY20: 536.9M FY21: 320.2M FY22: -34.1M FY23: -206.3M FY24: 58.7M FY25: 170.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-300M -150M 0 150M 300M 450M FY09: -3.4M FY10: 75.9M FY11: -41.8M FY12: -14.2M FY13: 54.9M FY14: 81.6M FY15: -2.3M FY16: -21.6M FY17: 153.3M FY18: -30.3M FY19: 101.1M FY20: 395M FY21: 96.1M FY22: -149.9M FY23: -257.9M FY24: 35.8M FY25: 156.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY09: 31.4M FY10: 32.5M FY11: 36.2M FY12: 36.4M FY13: 36.7M FY14: 45.8M FY15: 47.3M FY16: 49.3M FY17: 50.3M FY18: 51.4M FY19: 52.4M FY20: 53.8M FY21: 54.1M FY22: 50.1M FY23: 51.2M FY24: 53M FY25: 56.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '10: 1.59 Q1 '11: 0.90 Q2 '11: 0.98 Q3 '11: 0.61 Q4 '11: 0.60 Q1 '12: 1.02 Q2 '12: 0.84 Q3 '12: 0.98 Q4 '12: 0.64 Q1 '13: 0.61 Q2 '13: 0.69 Q3 '13: 0.87 Q4 '13: 0.84 Q1 '14: 0.51 Q2 '14: 0.35 Q3 '14: 0.48 Q4 '14: 0.73 Q1 '15: 0.71 Q2 '15: 0.90 Q3 '15: 1.20 Q4 '15: 1.25 Q1 '16: 1.92 Q2 '16: 1.33 Q3 '16: 0.99 Q4 '16: 1.05 Q1 '17: 1.18 Q2 '17: 1.56 Q3 '17: 1.79 Q4 '17: 1.70 Q1 '18: 1.37 Q2 '18: 2.24 Q3 '18: 1.97 Q4 '18: 1.22 Q1 '19: 0.81 Q2 '19: -0.35 Q3 '19: 0.07 Q4 '19: 1.04 Q1 '20: 1.31 Q2 '20: 3.22 Q3 '20: 3.12 Q4 '20: 5.66 Q1 '21: 7.18 Q2 '21: 5.54 Q3 '21: 4.20 Q4 '21: 4.36 Q1 '22: 2.99 Q2 '22: 1.84 Q3 '22: 0.70 Q4 '22: -4.24 Q1 '23: -7.86 Q2 '23: -11.96 Q3 '23: -15.29 Q4 '23: -14.83 Q1 '24: -10.95 Q2 '24: -11.17 Q3 '24: -4.03 Q4 '24: -3.60 Q1 '25: -2.58 Q2 '25: 2.58 Q3 '25: 1.43 Q4 '25: 0.93 Q1 '26: -0.19 Q2 '26: -3.46 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.